Optimal Additional Therapy to Ezetimibe for LDL Lowering

Primary Recommendation

The American College of Cardiology recommends adding a high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) to ezetimibe as the first-line combination therapy for LDL lowering in patients with hyperlipidemia, providing an additional 50-60% LDL-C reduction 1

For patients with diabetes, metabolic syndrome, or obesity, the American College of Cardiology suggests considering pitavastatin plus ezetimibe as the preferred combination, as pitavastatin may reduce or remain neutral regarding new-onset diabetes risk compared to other statins 2
Alternatively, using a lower-dose high-intensity statin (rosuvastatin 20 mg or atorvastatin 40 mg) plus ezetimibe can minimize diabetes risk while achieving significant LDL-C reduction 2

For patients with recent acute coronary syndrome (ACS), initiating simultaneous dual therapy with high-intensity statin plus ezetimibe immediately at discharge can achieve rapid LDL-C reduction and target LDL-C <55 mg/dL, supported by the IMPROVE-IT trial 1
For patients with severe primary hypercholesterolemia (LDL-C ≥190 mg/dL), starting with high-intensity statin plus ezetimibe targeting ≥50% LDL-C reduction and LDL-C <100 mg/dL is recommended 3
If LDL-C remains ≥100 mg/dL despite maximal tolerated statin plus ezetimibe, adding a PCSK9 inhibitor (evolocumab or alirocumab) can provide an additional 50-60% LDL-C reduction 1, 3

If LDL-C remains above goal on statin plus ezetimibe, adding a PCSK9 inhibitor (evolocumab, alirocumab, or inclisiran) can provide an additional 50-60% LDL-C reduction for patients with ASCVD not achieving LDL-C <55 mg/dL or <70 mg/dL depending on risk category 1, 2
Bile acid sequestrants (colesevelam 3.75 g daily) can provide an additional 18.5% LDL-C reduction but are limited by gastrointestinal side effects and drug interactions 3

Liver enzyme monitoring is recommended when combining ezetimibe with statins, and ezetimibe should be withdrawn if ALT or AST elevations ≥3× upper limit of normal persist 1
The combination of ezetimibe plus statin carries a similar myopathy risk to statin monotherapy, and most post-marking reports of rhabdomyolysis with ezetimibe occurred in patients taking statins or fibrates 1

The American College of Cardiology recommends maximizing statin therapy first, targeting ≥50% LDL-C reduction and LDL-C <70 mg/dL, before adding ezetimibe 4, 5
Ezetimibe 10 mg daily is recommended when maximally tolerated statin fails to achieve LDL-C <70 mg/dL or ≥50% reduction, providing an additional 20-25% LDL-C reduction 4, 6

For patients with ASCVD, the European Society of Cardiology recommends a treatment target of LDL-C <55 mg/dL, and may initiate simultaneous dual nonstatin therapy (ezetimibe plus PCSK9 inhibitor) with statin to achieve rapid risk reduction 4, 5
The American College of Cardiology suggests that ezetimibe monotherapy is recommended as first-line therapy in high and very high-risk patients who cannot tolerate any statin dose, with an expected LDL-C reduction of 15-20% 6, 7

The American College of Cardiology states that ezetimibe provides complementary LDL-C lowering through a distinct mechanism, inhibiting NPC1L1 protein in the small intestine, and demonstrates excellent tolerability with adverse effects similar to placebo when used as monotherapy 6
The European Heart Journal reports that ezetimibe has a synergistic effect when combined with statins, achieving 34-61% total LDL-C reduction, and is preferred over PCSK9 inhibitors as initial nonstatin therapy due to lower cost and oral administration 4, 7

The American College of Cardiology advises to avoid using ezetimibe for triglyceride lowering, as it provides only modest triglyceride reduction (10-15%), and to consider adding PCSK9 inhibitor if goals are not met 6, 8
The Journal of the American College of Cardiology recommends evaluating medication adherence and lifestyle modifications before escalating therapy, and considering simultaneous initiation of statin plus ezetimibe in patients with recent ACS or recurrent events to achieve rapid LDL-C reduction 5